靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2021.01.015

摘要/Abstract

摘要： 成纤维细胞生长因子受体(Fibroblast growth factor receptors,FGFRs)通过与配体-成纤维细胞生长因子(FGFs)结合调节细胞的生长、增殖和血管生成等。越来越多的研究表明FGFRs信号是恶性肿瘤的驱动因素,在肿瘤血管生成和癌细胞分裂增殖的过程中起重要作用。本文就FGFRs信号通路在生理、病理以及恶性肿瘤中的作用机制做一综述,为临床上开发靶向抑制FGFRs信号、完善肿瘤治疗方案提供依据。

关键词: 成纤维生长因子, 恶性肿瘤, 作用机制, 靶向治疗

Abstract: Fibroblast growth factor receptors(FGFRs)regulates cell growth,proliferation and angiogenesis by binding with ligand fibroblast growth factors(FGFs).More and more studies have shown that FGFRs are the driving factor of some malignant tumors,and play an important role in the process of tumor angiogenesis and tumor cell division and proliferation.This article reviews the mechanism of FGFRs signaling pathway in physiology,pathology and malignant tumor,and provides a basis for clinical development for targeted inhibition of FGFRs signaling and the improvement of tumor treatment programs.

Key words: Fibroblast growth factors, Malignant tumors, Mechanism of action, Targeted therapy

中图分类号:

杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.

YANG Siqi,SONG Qibin,LI Qingqing,YAO Yi. Research progress of targeted inhibition of FGFRs signal in the treatment of malignant tumors[J]. Journal of Practical Oncology, 2021, 35(1): 73-77.

参考文献

1 Babina IS,Turner NC.Advances and challenges in targeting FGFR signalling in cancer[J].Nat Rev Cancer,2017,17(5):318.
2 Nobuyuki I,Ornitz DM.Fibroblast growth factors:from molecular evolution to roles in development,metabolism and disease[J].J Biochem,2011,149(2):121-130.
3 邢志超,麦威.脂肪肉瘤潜在作用靶点的研究进展[J].实用肿瘤学杂志,2019,33(1):88-92.
4 Perez-Garcia J,Muoz-Couselo E,Soberino J,et al.Targeting FGFR pathway in breast cancer[J].Breast,2017,37(7):126-133.
5 Fan JY,Li YW,Jia RB,et al.An inherited FGFR2 mutation increased osteogenesis gene expression and result in Crouzon syndrome[J].BMC Med Gene,2018,19(1):91.
6 Zhang Y,Zheng DF,Li Y,et al.Comprehensive investigation of clinicopathologic features,oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma[J].J Thorac Dis,2017,9(11):4434.
7 Yang Z,Zhang RY,Ge YX,et al.Somatic,FGFR3,mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy[J].Ebiomedicine,2018,35(5):25-30.
8 Hanker AB,Garrett JG,Estrada MV,et al.HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2[J].Clin Cancer Res,2017,23(15):4323-4334.
9 Montor WR,Salas AROSE,de Melo FHM.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment:the current arsenal of inhibitors[J].Mol Cancer,2018,17(1):55.
10 Sobhani N,Ianza A,D'Angelo A,et al.Current status of fibroblast growth factor receptor-targeted therapies in breast cancer[J].Cells,2018,7(7):76.
11 Yang W,Yao YW,Zeng JL,et al.Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer:A meta-analysis[J].J Thorac Dis,2014,6(6):803-809.
12 Malchers F,Ercanoglu M,Schütte D,et al.Mechanisms of primary drug resistance in FGFR1 amplified lung cancer[J].Clin Cancer Res,2017,23(18):78-80.
13 Ishiwata T,Yoshiruma H,Matsuda Y,et al.Abstract 4577:Fibroblast growth factor receptor-4(FGFR-4)as a novel therapeutic target for pancreatic cancer[J].Cancer Res,2016,76(14):4577-4577.
14 Lamont FR,Tomlison DC,Cooper PA,et al.Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.[J].British J Cancer,2011,104(1):75-82.
15 De Luca A,Frezzetti D,Gallo M,et al.FGFR-targeted therapeutics for the treatment of breast cancer[J].Expert Opin Inv Drugs,2017,26(3):303.
16 Hu P,Chen H,Mcgowan E,et al.Assessment of FGFR1 overexpression and over-activity in lung cancer cells:a toolkit for anti-FGFR1 drug screening[J].Hum Gene Ther Method,2017,18(4):227-229.
17 刘佳骅,倪醒之.成纤维细胞生长因子受体4在恶性肿瘤中的作用[J].实用医学杂志,2010,26(3):511-512.
18 Hu Y,Hsu W.FGFR1/MAPK pathway regulates transcription factor brachyury-driven epithelial-mesenchymal transition in lung cancer[J].Cancer Res,2015,75(15):2079.
19 Tsunoda S,Nakamura T,Sakurai H,et al.Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization[J].Cancer Sci,2007,98(4):541-548.
20 Thomson S,Petti F,Sujka-Kwok I,et al.Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy[J].Clin Exp Metastas,2008,25(8):843-854.
21 Xu M,Chen S,Yang W,et al.FGFR4 links glucose metabolism and chemotherapy resistance in breast cancer[J].Cell Physio Biochem,2018,47(1):151-160.
22 Sun C,Fang L,Gou S.Discovery of a Novel FGFR4 Selective Inhibitor via Structure-Activity Relationship Studies of FGF401[J].Chinese J Org Chem,2020,40(1):84.
23 Piasecka D,Braun M,Kitowska K,et al.FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors-implications for therapy of luminal breast cancer[J].J Experimental Clin Cancer Res,2019,38(230): 1-12.
24 Mcleskey SW,Powers CJ,Wellstein A.Fibroblast growth factors,their receptors and signaling[J].Endocrine Related Cancer,2000,7(3):165-197.
25 Moyal CJ,Ader I,Delmas C,et al.Targeting FGFR-1 pathways by the antagonist SSR128129E overcomes the radioresistance of human glioma in vitro and in vivo[J].Int J Radiat Oncol,2009,75(3):70.
26 Darren RC,Rebekah HG,Yu X,et al.Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres[J].J Vasc Intervl Radiol,2014,25(2):297-306.
27 Grünewald S,Politz O,Bender S,et al.Rogaratinib:a potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models[J].Int J Cancer,2019,145(5):1346-1357.
28 Kikuchi A,Suzuki T,Nakazawa T,et al.ASP5878,a selective FGFR inhibitor,to treat FGFR3-dependent urothelial cancer with or without chemoresistance[J].Cancer Sci,2017,108(2):236-242.
29 Tiseo M.FGFR as potential target in the treatment of squamous non small cell lung cancer[J].Cancer Treat Rev,2015,41(6):527-539.
30 Nogova L,Sequist LV,Perez Garcia JM,et al.Evaluation of BGJ398,a fibroblast growth factor receptor 1-3 kinase inhibitor,in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors:results of a global phase I,dose-escalation and dose-expansion study[J].J Clin Oncol,2016,35(2):48-50.
31 Wen J,Xue Y,Ming T,et al.Recent developments and advances of FGFR as a potential target in cancer.[J].Future Med Chem,2018,10(17):103-105.
32 Brummelen EMJV.A phase Ib study of GSK3052230,an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma[J].Future Med Chem,2019,16(5):15-19.
33 Goyal L,Saha SK,Liu LY,et al.Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma[J].Cancer Discov,2017,7(3):1000-1016.
34 Brands R,Knierim L,De Donno F,et al.Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro[J].Oncol Rep,2017,38(3):1877-1885.
35 Javle M,Lowery M,Shroff RT,et al.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J].J Clin Oncol,2018,36(3):509-511.
36 Liang D,Chen Q,Guo Y,et al.Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study[J].Drug Des Dev Ther,2017,11(6):451-461.
37 Kelly CM,Shoushtari AN,Qin LX,et al.A phase Ib study of BGJ398,a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor[J].Invest New Drugs,2019,37(2):282-290.
38 Wu D.LY2874455 potently inhibits FGFR gatekeeper mutant and overcomes mutation-based resistance[J].Chem Commun,2018,54(85):12089-12092.
39 Santoni-Rugiu E,Grauslund M,Melchior LC,et al.Heterogeneous resistance mechanisms in an,EGFR,exon 19-mutated non-small cell lung cancer patient treated with erlotinib:persistent,FGFR3-mutation,localized transformation to,EGFR-mutated SCLC,and acquired T790M,EGFR-mutation[J].Lung Cancer,2017,113(8):14-17.
40 Baschnagel AM,Li C,Morgan AM,et al.Abstract 1094:Combining the pan-FGFR inhibitor AZD4547 with radiation in lung and head and neck squamous cell carcinoma[J].Cancer Res,2017,77(13):1094-1094.
41 Packer LM,Geng X,Bonazzi VF,et al.PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2-mutant endometrial cancers[J].Mol Cancer Ther,2017,16(4):637-648.
42 Kristina G,Lydia M,Mirjam K,et al.Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer[J].Oncogene,2018,37(3):5682-5693.
43 Sun Y K,Ahn T,Bang H,et al.Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion[J].Oncotarget,2017,8(9):1182-1186.
44 Yu Y,Hall T,Eathiraj S,et al.In-vitro and in-vivo combined effect of ARQ 092,an AKT inhibitor,with ARQ 087,a FGFR inhibitor[J].Anticancer Drug,2017,28(5):503-513.

[1]	郑志远,综述,曲国蕃(审校). 长链非编码RNA SNHG3在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 50-54.
[2]	文洪梅, 陈杨, 石青萍, 任思颖, 高娇, 秦明芳. 2016年云南省肿瘤登记地区恶性肿瘤的发病和死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 485-490.
[3]	相智声, 马晶昱, 钟文玲, 陈铁晖, 林永添, 江惠娟, 周衍. 福建省2016年恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2020, 34(6): 491-494.
[4]	李建昕, 沈彬杰, 王璇. 恶性肿瘤社区随访模式的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 540-543.
[5]	宋家羽, 冯越, 王棹, 张云艳. 外泌体与妇科恶性肿瘤相关性的最新研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 571-575.
[6]	韩仁强, 武鸣, 缪伟刚, 罗鹏飞, 俞浩, 周金意. 2016年江苏省恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 291-297.
[7]	马芳, 丁晨哲, 魏嵘, 张银娥, 赵建华, 陈婧鑫. 2016年宁夏肿瘤登记地区恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2020, 34(4): 298-303.
[8]	成姝雯, 董婷, 曾晶, 胥馨尹, 邓颖, 张新. 2015年四川省肿瘤登记地区恶性肿瘤发病和死亡情况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 304-308.
[9]	穆慧娟, 礼彦侠, 于丽娅, 张蕊, 李爽, 那军, 马祥, 刘莉, 田疆. 2016年辽宁省肿瘤登记地区恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 309-314.
[10]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[11]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[12]	孙坤, 王冲, 沈成凤, 张爽, 张辉, 宋桂德, 王卓, 王德征. 2015年天津市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2020, 34(2): 114-119.
[13]	林玉华, 倪振华, 孙亦鹏, 毕俊杰, 王雄彪. SPDEF与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2020, 34(2): 185-188.
[14]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[15]	包乐, 唐丽萍. EphB6受体在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 83-87.